Latest period
$13.61B
YoY change
+91.4%
5Y CAGR
+31.7%
Peak year (2025)
$14.05B
Cumulative CapEx
$49.60B
CapEx history chart for Novo Nordisk (NVO) from 1990 to 2025
Latest: $14.05B
CapEx growth chart for Novo Nordisk (NVO) from 1990 to 2025
Latest: +91.4%
CapEx history table for Novo Nordisk (NVO) from 1990 to 2025
| 2025 | $14.05B | +91.4% | +$6.71B | ||
| 2024 | $7.34B | +30.7% | +$1.72B | ||
| 2023 | $5.61B | +177.0% | +$3.59B | ||
| 2022 | $2.03B | +78.5% | +$891.78M | ||
| 2021 | $1.14B | -67.9% | −$2.40B | ||
| 2020 | $3.54B | +112.6% | +$1.87B | ||
| 2019 | $1.66B | -12.3% | −$232.77M | ||
| 2018 | $1.90B | +38.6% | +$528.81M | ||
| 2017 | $1.37B | +14.2% | +$170.55M | ||
| 2016 | $1.20B | +27.4% | +$257.52M | ||
| 2015 | $940.38M | +29.3% | +$212.98M | ||
| 2014 | $727.40M | +9.4% | +$62.24M | ||
| 2013 | $665.16M | +5.6% | +$35.08M | ||
| 2012 | $630.09M | +4.4% | +$26.67M | ||
| 2011 | $603.42M | -15.0% | −$106.44M | ||
| 2010 | $709.86M | +16.7% | +$101.74M | ||
| 2009 | $608.12M | +68.0% | +$246.08M | ||
| 2008 | $362.05M | -23.3% | −$109.86M | ||
| 2007 | $471.91M | -17.8% | −$102.01M | ||
| 2006 | $573.92M | -7.6% | −$47.25M | ||
| 2005 | $621.16M | +12.5% | +$68.88M | ||
| 2004 | $552.28M | +32.8% | +$136.51M | ||
| 2003 | $415.77M | — | — | ||
| 2002 | — | — | — | ||
| 2001 | — | — | — | ||
| 2000 | — | — | — | ||
| 1999 | — | — | — | ||
| 1998 | — | — | — | ||
| 1997 | — | — | — | ||
| 1996 | — | — | — | ||
| 1995 | — | — | — | ||
| 1994 | — | — | — | ||
| 1993 | — | — | — | ||
| 1992 | — | — | — | ||
| 1991 | — | — | — | ||
| 1990 | — | — | — |
- 2025$14.05B+91.4%
- 2024$7.34B+30.7%
- 2023$5.61B+177.0%
- 2022$2.03B+78.5%
- 2021$1.14B-67.9%
- 2020$3.54B+112.6%
- 2019$1.66B-12.3%
- 2018$1.90B+38.6%
- 2017$1.37B+14.2%
- 2016$1.20B+27.4%
- 2015$940.38M+29.3%
- 2014$727.40M+9.4%
- 2013$665.16M+5.6%
- 2012$630.09M+4.4%
- 2011$603.42M-15.0%
- 2010$709.86M+16.7%
- 2009$608.12M+68.0%
- 2008$362.05M-23.3%
- 2007$471.91M-17.8%
- 2006$573.92M-7.6%
- 2005$621.16M+12.5%
- 2004$552.28M+32.8%
- 2003$415.77M—
- 2002——
- 2001——
- 2000——
- 1999——
- 1998——
- 1997——
- 1996——
- 1995——
- 1994——
- 1993——
- 1992——
- 1991——
- 1990——
CapEx values are taken from Novo Nordisk's reported cash flow statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About CapEx at Novo Nordisk (NVO)
According to Novo Nordisk's latest reported financial statements, the company's current CapEx (TTM) is $13.61B. Capital expenditures (CapEx) are cash outlays for property, plant, and equipment and other long-lived productive assets — reported on the cash flow statement under investing activities. CapEx funds future capacity (factories, data centers, software, machinery), so rising spend can signal investment in growth, while heavy CapEx reduces free cash flow available to shareholders. We display CapEx as a positive amount (the absolute cash outflow); compare with revenue to gauge capital intensity and with total assets for the asset-base context.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Novo Nordisk (NVO) most recent annual CapEx stands at 90.11B DKK (2025) – surged 75.6% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Novo Nordisk CapEx compounded at +32.5% per year, sustaining 4 straight years of year-over-year growth.
Across the available history, CapEx reached its high of 90.11B DKK in 2025 and its low of 1.17B DKK in 1990.
Novo Nordisk Capital Expenditures by Year
Novo Nordisk Capital Expenditures 2025: $14.05B
Novo Nordisk posted CapEx of 90.11B DKK ($14.05B) in 2025, surged 75.6% from 2024. This figure represents the highest annual value in the available history.
Novo Nordisk Capital Expenditures 2024: $7.34B
In 2024, Novo Nordisk reported CapEx of 51.31B DKK ($7.34B), surged 31.9% from 2023.
Novo Nordisk Capital Expenditures 2023: $5.61B
Novo Nordisk CapEx in 2023 was 38.90B DKK ($5.61B), surged 163.6% from 2022.
Novo Nordisk Capital Expenditures 2022: $2.03B
2022's CapEx for Novo Nordisk came in at 14.75B DKK ($2.03B), surged 99.8% from 2021.
Novo Nordisk Capital Expenditures 2021: $1.14B
Novo Nordisk CapEx in 2021 was 7.38B DKK ($1.14B).
See more financial history for Novo Nordisk (NVO).
Sector peers by CapEx
Healthcare peers of Novo Nordisk (NVO), ranked by their latest CapEx
| $7.84B | |
| $4.83B | |
| $4.11B | |
| $3.62B | |
| $2.81B | |
| $1.86B | |
| $1.52B | |
| $1.21B |
- $7.84B
- $4.83B
- $4.11B
- $3.62B
- $2.81B
- $1.86B
- $1.21B
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation